Why did DBV.PA stock surge today?

DBV.PA stock rose after the company reported full exercise of warrants that added €166.70 million and because the market is re-pricing the positive VITESSE Phase III topline results for VIASKIN® Peanut

What is Meyka AI's rating for DBV.PA stock?

Meyka AI rates DBV.PA with a score of 63.69 out of 100, Grade B, suggestion HOLD. The grade factors benchmark, sector, growth, metrics and analyst consensus

What price targets and forecasts exist for DBV.PA stock?

Near-term technical resistance is around €3.91 and year high €4.50. Meyka AI's five-year forecast is €4.56 (approx +21.88% vs €3.74) and one-year model is €1.69; forecasts are projections, not guarantees

What are the main risks for DBV.PA stock holders?

Key risks include dilution from outstanding pre-funded warrants, continued negative EPS (-0.89), high R&D burn, and regulatory or clinical setbacks that could reverse sentiment

EU Stocks

DBV.PA DBV Technologies (EURONEXT) up 20.84% intraday: volume spike signals follow-through

ByDanny Kontos January 19, 2026January 19, 2026

DBV.PA stock is trading sharply higher 20.84% intraday at €3.74 on EURONEXT on heavy volume, up from a previous close of €3.10. The move follows DBV Technologies S.A. news of a €166.70 million financing tranche and continued market reaction to positive VITESSE trial results. Volume today is 2,998,423 versus an average of 1,357,076, a clear high-volume mover signal that traders and institutions are watching closely